MHYS Stock Chart ALL AVEW TRTC NXTD

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Rosti Bets on Expansion with Alvi Buyout Rosti Group just rolled the dice big by swallowing Alvi Group, marking another bold move in the ever-swinging industrial and medical device manufacturing rodeo. Suddenly, we’re talking about a company with roughly 3,000 employees on its roster and a neat EUR 450 million in combined revenue. Don't overlook the power play...

Stocks Lift as Wall Street Awaits Inflation Data Every trader's favorite game—speculation—returns as major U.S. stock benchmarks kick off Monday with some gusto. The S&P 500, Nasdaq Composite, Dow Jones Industrial Average, and Russell 2000 all saw gains in the early morning session, signaling positive vibes across the board. Numbers don't lie, folks: The S&P climbed...

Paul Taubman Steers the Ship at CSHL Here's the buzz coming out of Cold Spring Harbor Lab: they're handing the reins over to Paul Taubman. It's like swapping captains in the middle of the ocean—big shoes need to stay afloat. This place isn't just the playground for science nerds; it's a powerhouse in biomedical research. Now, we've got Taubman, a fella who's been...

Turning Heads with a New Approach in Immunotherapy Right off the bat, let's say something's brewing in the world of cancer treatment, and it's got a promising name: BND-67. We're talking about Biond Biologics, an ambitious Israeli outfit aiming to rewrite the rules with their new kid on the block in immunotherapies. This isn't about business as usual. It's about a fresh...

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Pioneering a New Path in Dermatology Treatment In the world of dermatology, finding a topical solution that tackles the full spectrum of atopic dermatitis (AD) is as rare as hens' teeth. But here's a twist—in a recent research paper gracing the Journal of Drugs in Dermatology, Alphyn Biologics sheds light on their unique contender, Zabalafin Hydrogel. This ain't your...

Riding the Roller Coaster of Financials Crack open the books, and there's more than meets the eye with ADC Therapeutics this quarter. We're talking a $21 million haul in product revenue—that's nothing to sneeze at. Things are heating up with their balance sheet, thanks to a strategic restructuring that's stretching their cash runway out to 2029. That’s some...

The Breakthrough in Edge Computing Everyone's talking about cloud this and cloud that, but Tencent Cloud is taking things a notch further with its EdgeOne platform. It's not just about storing your files in the sky; it's about having the fastest, most secure delivery possible. Gartner's latest report puts these guys right at the top in their Magic Quadrant for Edge...

Starwood Property Trust Expands Private Offering of Bonds Starwood Property Trust, Inc. (NYSE: STWD) has made a significant announcement regarding its latest financial maneuver. The company has priced its private offering, which has now been upsized to an impressive $500 million. This offering involves unsecured senior notes with a fixed interest rate of 6.500% due in...

Prime Medicine (NASDAQ: PRME) landed a hefty collaboration with Bristol Myers Squibb (NYSE: BMY) back in 2024, worth a cool $110 million. The breakdown? A sweet $55 million upfront payment paired with another $55 million as an equity investment. Now, this kind of cash infusion had traders buzzing—just what they needed to keep the lights on until at least mid-2026. But...

Truly Hard Seltzer Introduces the Innovative Rain Check Program Summer is a season of joy, sunshine, and outdoor gatherings, but unpredictable weather can put a damper on plans. As we approach July, many anticipate pool parties and barbecues. However, with increased rainfall patterns reported in various regions, July 4th celebrations might not go as planned. To help fans...

Top Cybersecurity Tips for the Holiday Season As the holiday season approaches, it presents a myriad of opportunities for shoppers and cybercriminals alike. KnowBe4, a leader in cybersecurity solutions and training, highlights the need for awareness among consumers. This year, the company announces their top five cybersecurity tips aimed at helping shoppers stay safe and...

Plaza Retail REIT Announces New Leadership Plaza Retail REIT has officially communicated an exciting shift in its leadership structure. Jason Parravano will take over the role of President & CEO, succeeding Michael Zakuta, who will remain actively involved with the Trust as a Trustee. This leadership transition signifies Plaza's commitment to continuing its strategic...